Lexicon Pharmaceuticals (LXRX) Enterprise Value (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Enterprise Value data on file, last reported at -$170.7 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 12.41% year-over-year to -$170.7 million in Q1 2026; TTM through Mar 2026 was -$170.7 million, a 12.41% increase from a year earlier, with the FY2025 full-year figure at -$96.2 million, up 59.56% from the prior year.
• Enterprise Value for Q1 2026 stood at -$170.7 million, down from -$96.2 million in the prior quarter.
• Over the last five years, Enterprise Value for LXRX reached as high as -$62.0 million in Q2 2022 and fell as low as -$355.6 million in Q1 2024.
• Historically, Enterprise Value has averaged -$179.6 million across 5 years, with a median of -$170.0 million in 2023.
• Across the five-year window, Enterprise Value slumped 314.31% in 2023 and jumped 59.56% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$138.4 million in 2022, then dropped by 22.89% to -$170.0 million in 2023, then sank by 39.95% to -$238.0 million in 2024, then soared by 59.56% to -$96.2 million in 2025, then tumbled by 77.34% to -$170.7 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$170.7 million in Q1 2026, -$96.2 million in Q4 2025, and -$116.0 million in Q3 2025.